These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 30373998)

  • 1. [Bone and calcium metabolism associated with malignancy. Bone and calcium metabolism associated with malignancy.].
    Ishikawa T
    Clin Calcium; 2018; 28(11):1431-1440. PubMed ID: 30373998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone modifying agents for patients with bone metastases from breast cancer managed in routine practice setting: Treatment patterns and outcome.
    Zekri J; Farag K; Yousof O; Zabani Y; Mohamed W; Ahmed GA
    J Oncol Pharm Pract; 2020 Jun; 26(4):906-911. PubMed ID: 31575357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of denosumab and zoledronic acid for the treatment of solid tumors and multiple myeloma with bone metastasis: a systematic review and meta-analysis based on randomized controlled trials.
    Jiang L; Cui X; Ma H; Tang X
    J Orthop Surg Res; 2021 Jun; 16(1):400. PubMed ID: 34158101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.
    Raje N; Terpos E; Willenbacher W; Shimizu K; García-Sanz R; Durie B; Legieć W; Krejčí M; Laribi K; Zhu L; Cheng P; Warner D; Roodman GD
    Lancet Oncol; 2018 Mar; 19(3):370-381. PubMed ID: 29429912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in the United States.
    Henry D; von Moos R; Body JJ; Rider A; De Courcy J; Bhowmik D; Gatta F; Hechmati G; Qian Y
    Curr Med Res Opin; 2019 Mar; 35(3):375-381. PubMed ID: 30550358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Denosumab Versus Zoledronic Acid in the Prevention of Skeletal-related Events in Vulnerable Cancer Patients: A Meta-analysis of Randomized, Controlled Trials.
    Chen C; Li R; Yang T; Ma L; Zhou S; Li M; Zhou Y; Cui Y
    Clin Ther; 2020 Aug; 42(8):1494-1507.e1. PubMed ID: 32718784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of denosumab for the prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
    Stopeck A; Brufsky A; Kennedy L; Bhatta S; Bhowmik D; Buchanan J; Despiegel N; Hechmati G
    J Med Econ; 2020 Jan; 23(1):37-47. PubMed ID: 31364885
    [No Abstract]   [Full Text] [Related]  

  • 8. Bisphosphonates and other bone agents for breast cancer.
    Wong MH; Stockler MR; Pavlakis N
    Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of denosumab versus zoledronic acid on calcium levels in cancer patients with bone metastasis: A retrospective cohort study.
    Nasser SM; Sahal A; Hamad A; Elazzazy S
    J Oncol Pharm Pract; 2019 Dec; 25(8):1846-1852. PubMed ID: 31694497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comprehensive review of denosumab for bone metastasis in patients with solid tumors.
    Gül G; Sendur MA; Aksoy S; Sever AR; Altundag K
    Curr Med Res Opin; 2016; 32(1):133-45. PubMed ID: 26451465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update Summary.
    Van Poznak C; Somerfield MR; Moy B
    J Oncol Pract; 2017 Dec; 13(12):822-824. PubMed ID: 29035617
    [No Abstract]   [Full Text] [Related]  

  • 12. Antiresorptive agent-related osteonecrosis of the jaw in prostate cancer patients with bone metastasis treated with bone-modifying agents.
    Nakai Y; Kanaki T; Yamamoto A; Tanaka R; Yamamoto Y; Nagahara A; Nakayama M; Kakimoto KI; Ishibashi M; Nishimura K
    J Bone Miner Metab; 2021 Mar; 39(2):295-301. PubMed ID: 32886176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy: a retrospective study and systematic review.
    Takahashi M; Ozaki Y; Kizawa R; Masuda J; Sakamaki K; Kinowaki K; Umezu T; Kondoh C; Tanabe Y; Tamura N; Miura Y; Shigekawa T; Kawabata H; Baba N; Iguchi H; Takano T
    BMC Cancer; 2019 Oct; 19(1):980. PubMed ID: 31640606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Inhibition of RANK ligand to treat bone metastases].
    Body JJ
    Bull Cancer; 2013 Nov; 100(11):1207-13. PubMed ID: 24158618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High serum ALP level is associated with increased risk of denosumab-related hypocalcemia in patients with bone metastases from solid tumors.
    Kinoshita Y; Arai M; Ito N; Takashi Y; Makita N; Nangaku M; Shinoda Y; Fukumoto S
    Endocr J; 2016 May; 63(5):479-84. PubMed ID: 26860123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
    Henry DH; Costa L; Goldwasser F; Hirsh V; Hungria V; Prausova J; Scagliotti GV; Sleeboom H; Spencer A; Vadhan-Raj S; von Moos R; Willenbacher W; Woll PJ; Wang J; Jiang Q; Jun S; Dansey R; Yeh H
    J Clin Oncol; 2011 Mar; 29(9):1125-32. PubMed ID: 21343556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for skeletal-related events in patients with bone metastasis from breast cancer undergoing treatment with zoledronate.
    Miyashita H; Cruz C; Malamud S
    Breast Cancer Res Treat; 2020 Jul; 182(2):381-388. PubMed ID: 32474744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Denosumab versus zoledronic acid for preventing symptomatic skeletal events in Asian postmenopausal women with oestrogen-receptor-positive advanced breast cancer: an outcome analyses with a mean follow-up of 3 years.
    Zhang C; Zhang F; Liang G; Zeng X; Yu W; Jiang Z; Ma J; Zhao M; Xiong M; Gui K; Yuan F; Ji W
    BMC Musculoskelet Disord; 2018 Nov; 19(1):424. PubMed ID: 30497434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Zoledronic Acid and Denosumab Treatment on Growth Factor Concentration in Platelet Rich Fibrin of Patients With Osteolytic Bone Metastases.
    Steller D; Simon R; Von Bialy R; Hakim SG; Pries R
    Anticancer Res; 2021 Aug; 41(8):3917-3923. PubMed ID: 34281854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Symptomatic hypocalcemia following a single dose of zoledronic acid in a patient with bone metastases secondary to breast cancer.
    Sözel H; Yilmaz F
    J Oncol Pharm Pract; 2021 Mar; 27(2):494-497. PubMed ID: 32660376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.